Stryker Price Targets Raised to $469 and $454 on Strong Q4 Performance
Stryker’s price target was raised to $469, signaling over 23% upside, while Needham lifted its target to $454, implying nearly 20% upside. The company’s fourth-quarter revenue and EPS exceeded expectations thanks to high procedure volumes, new product offerings and a backlog of capital equipment orders.
1. Barclays Boosts Price Target
On February 2, Barclays raised its price target on Stryker from $462 to $469, reaffirming an Overweight rating and indicating more than 23% upside potential based on the firm’s 2026 growth model.
2. Needham Raises Target After Q4 Beat
On January 30, Needham analyst Mike Matson reiterated a Buy rating and increased his price target for Stryker from $448 to $454, reflecting almost 20% upside and confidence in the company’s outlook.
3. Q4 Drivers: Volumes and Backlog
Analysts highlighted Stryker’s fourth-quarter revenue and EPS outperformance, driven by elevated procedure volumes, new medical-device offerings and a backlog of capital equipment orders across its MedSurg & Neurotechnology and Orthopaedics segments.